Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States.
It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform.
It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals,S. L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design,Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.07 Decreased by -332.33% | - |
| Mar 28, 24 | -0.08 Decreased by -14.29% | -0.06 Decreased by -33.33% |
| Nov 8, 23 | -0.06 Increased by 0.00% | -0.06 |
| Aug 9, 23 | -0.07 Increased by +41.67% | -0.05 Decreased by -40.00% |
| May 10, 23 | 0.03 Increased by +133.33% | - |
| Mar 29, 23 | -0.07 Increased by +53.33% | -0.08 Increased by +12.50% |
| Nov 10, 22 | -0.06 Increased by 0.00% | -0.09 Increased by +33.33% |
| Aug 10, 22 | -0.12 Increased by +14.29% | -0.09 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 397.06 K Decreased by -54.86% | -1.61 M Increased by +5.08% | Decreased by -406.55% Decreased by -110.28% |
| Jun 30, 23 | 837.16 K Increased by +27.12% | -2.15 M Increased by +33.30% | Decreased by -257.17% Increased by +47.53% |
| Mar 31, 23 | 978.05 K Increased by +50.83% | 137.61 K Increased by +106.15% | Increased by +14.07% Increased by +104.08% |
| Dec 31, 22 | 743.73 K Increased by +137.39% | -2.07 M Increased by +50.82% | Decreased by -278.62% Increased by +79.29% |
| Sep 30, 22 | 879.60 K Increased by +26.94% | -1.70 M Increased by +0.86% | Decreased by -193.34% Increased by +21.90% |
| Jun 30, 22 | 658.55 K Decreased by -29.72% | -3.23 M Increased by +16.07% | Decreased by -490.16% Decreased by -19.42% |
| Mar 31, 22 | 648.43 K Increased by +40.80% | -2.24 M Increased by +32.15% | Decreased by -344.79% Increased by +51.81% |
| Dec 31, 21 | 313.29 K Decreased by -9.43% | -4.21 M Decreased by -114.97% | Decreased by -1.35 K% Decreased by -137.36% |